RxDoctor Payments Data

Jose Adorno Fontanez, MD

Internal Medicine · Caguas, PRNPI 1306040787

Payments from drug & device makers

$1,416in general payments, 2019–2025

Across 59 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$293
  • Boehringer Ingelheim$279
  • GSK$264
  • Johnson & Johnson$240
  • Sanofi$69
  • Bayer$65
  • plus $207 from 5 others

What the payments were for

  • Food & beverage$1,39398%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca13$293
Boehringer Ingelheim12$279
GSK12$264
Johnson & Johnson7$240
Sanofi3$69
Bayer4$65
Gilead2$63
E.r. Squibb & Sons, L.L.C.2$57
Mylan LLC2$32
Olympus Latin America, Inc.1$32
Genentech USA, Inc.1$23

How this compares

$1,416 in reported general payments places this provider in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,735
Medicare patients
45
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$121,449
Spiriva RespimatTiotropium Bromide71$38,106
Breo ElliptaFluticasone/Vilanterol73$31,275
Albuterol Sulfate HfaAlbuterol Sulfate493$21,300
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate61$16,444
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$16,267
SymbicortBudesonide/Formoterol Fumarate44$10,362
Fluticasone Propionate HfaFluticasone Propionate36$8,731
Wixela InhubFluticasone Propion/Salmeterol39$6,207
Atrovent HfaIpratropium Bromide13$6,183
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$5,355
Levalbuterol Tartrate HfaLevalbuterol Tartrate49$2,950
Montelukast Sodium301$2,672
Fluticasone Propionate113$1,772
Tiotropium Bromide11$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$264$152,723254 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$279$54,373104 claims
AstraZenecaSymbicort$293$10,36244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →